Cory Kasimov is enthusiastic on GILD’s CAR-T therapy Yescarta as well as M&A strategy.
Gilead Sciences, Inc. (NASDAQ:GILD) shares fell nearly 4% in the extended session Thursday after the …
Cory Kasimov: GILD’s Phase II study data may be early, but first signs speak to a well-tolerated treatment.
Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.
Did this $4 billion fund make the right call on these two soaring biotechs?
Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the China Food and Drug Administration (CFDA) has approved …
Analyst questions the bigger picture for GILD, including risks and visibility challenges wavering in 2018.
Gilead is very confident on the successful commercial launch of Axi-Cel.
Kite acquisition signals Gilead’s leadership and continued consolidation moving forward, says Katherine Xu